Longevity medicine's do-or-die moment
A groundbreaking human trial has begun for a gene therapy aimed at partially reprogramming older cells to a younger state, a development that could validate key theories in the longevity medicine field. This early-stage clinical trial, sponsored by Life Biosciences and co-founded by David Sinclair, will first assess the safety of the therapy, which targets genes involved in cellular rejuvenation. While success in this trial would be a significant proof of concept, further efficacy trials will be needed to determine if the therapy can treat specific conditions like glaucoma, let alone reverse biological aging. AI
